MedTrace Logo

Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO)

NCT02720757 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 132

Last updated 2019-04-16

Study results available
· View outcomes & findings →

Summary

The primary objective of this Non Interventional Study is to measure changes in physical functioning, a surrogate for physical activity and exercise capacity, in COPD patients on treatment with Spiolto® Respimat® in routine daily treatment after approximately 6 weeks.

A secondary objective is to evaluate the patient's general condition (physician's evaluation) from Visit 1 (baseline visit at the start of the study) to Visit 2 (final visit at the end of the study, approx. 6 weeks after Visit 1), as well as patient satisfaction with Spiolto® Respimat® at Visit 2.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Spiolto Respimat

Tiotropium bromide + Olodaterol

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-26
Primary Completion
2017-12-14
Completion
2017-12-14

Countries

  • Belgium
  • Denmark
  • Luxembourg
  • Netherlands
  • Portugal
  • Sweden

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02720757 on ClinicalTrials.gov